208. ASCO 2026 - The Plenary Episode - Part 3

This episode is the ASCO 2026 Plenary Episode. This week, all of the pivotal, game-changing, life-changing trials are discussed here. Some describe the plenary session as practice-changing, and we will always agree that better treatments with significant improvements in life expectancy and quality of life need their time in the spotlight.Today, five trials are discussed, including SARC041, a liposarcoma study utilising the CDK 4/6 inhibigtor abemacicilib. Our second study is HARMONI-6, investigating whether ivonescimab plus chemotherapy is effective in patients with advanced squamous non-small cell lung cancer. Our third, almost like something written for an opera (LIBRETTO0-432), a lung cancer trial looking at selpercatinib in those with RET fusion early-stage NSCLCa. PROTEUS emerges as our fourth trial, rising from the depths of the ocean to evaluate apalutamide in the perioperative prostate cancer space.Finally, and most importantly in our opinion, is RASolute302, the pancreatic cancer trial, showing that even the most difficult mutation is now treatable. An incredible story of an exceptionally difficult cancer to treat, Daraxonrasib is the star of this year's ASCO.Studies Discussed in this EpisodeSARC041HARMONI-6LIBRETTO0-432PROTEUSRASolute302For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.